

PRESS RELEASE
21 February 2022 10:00:00 CET



SLG Kalmar AB - first private healthcare provider to receive reimbursement when using CoreFlow® - Soft Stent

SLG Kalmar AB receives, according to an agreement with Region Kalmar, as the first Swedish private urological clinic reimbursement for "stent treatment instead of catheter". The reimbursement level covers the purchase cost of ProstaLund's CoreFlow® - Soft Stent.

ProstaLund's CoreFlow® - Soft Stent is an innovative product designed to be used to temporarily resolve obstruction of the prostatic urethra. This function means that CoreFlow® has multiple areas of use for urologists, both as a treatment and in the examination of patients.

CoreFlow® - Soft Stent can, among other things, replace CAD (cathéter à demeure, indwelling catheter) for men, thereby radically reducing the risk of urinary tract infections. In addition, patients do not have to use a urine bag/valve linked to CAD, but can urinate on their own, which has a major impact on quality of life.

In Sweden alone, it is estimated that more than 40,000 men with benign prostate enlargement use CAD to empty their bladder. Not being able to empty the bladder and/or be treated with CAD poses a risk of healthcare-associated urinary tract infections. 80 percent of healthcare-associated urinary tract infections is caused by treatment with urinary catheters. The risk increases if patients with incontinence or urinary retention are not examined and treated correctly. CAD is the dominant cause of healthcare-associated urinary tract infections and overuse is high.

About ten days after insertion, all CAD carriers have bacterial growth in the bladder. The frequency is one febrile healthcare-associated urinary tract infection per 100 catheter days. The risk is particularly high in the event of urine flow obstruction. Catheter-related urinary tract infection is one of the most common healthcare-associated infections and leads to elevated morbidity, increased mortality, extended care time and thus increased costs. Apart from the suffering, it has been estimated that the complications related to healthcare-associated urinary tract infections of CAD-patients in Sweden cost society hundreds of millions of SEK per year. Healthcare-associated urinary tract infections have also been estimated to cause one death per one thousand hospitalizations due to catheters.

ProstaLund's CEO, Johan Wennerholm comments: "A very wise decision by the region. Using CoreFlow® - Soft Stent instead of indwelling catheters reduces both suffering and costs. "

More about CoreFlow® - Soft Stent: www.coreflow.se



PRESS RELEASE
21 February 2022 10:00:00 CET

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

SLG Kalmar AB - first private healthcare provider to receive reimbursement when using CoreFlow® - Soft Stent